{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62","upperLimit":"89","value":"75"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Determine the overall survival rate among all phase I trial participants who are treated with any of the 4 dose levels of oral clofarabine (1mg, 2mg, 4mg, or 3mg)","dispersionType":"90% Confidence Interval","groups":[{"description":"Clofarabine: Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.","id":"OG000","title":"Phase I"}],"paramType":"MEAN","populationDescription":"Phase I participants only","reportingStatus":"POSTED","timeFrame":"at 17 months","title":"All Phase I Participants: Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}